Thyroid safety is one of the most frequently asked questions about GLP-1 medications. Let's separate what the animal studies showed, what the human data says, and what actually needs monitoring.
GLP-1 receptor agonists carry an FDA black box warning for a type of thyroid cancer called medullary thyroid carcinoma (MTC) — based on rodent studies showing elevated risk. This has prompted caution and monitoring requirements.
Large observational studies in humans have not confirmed an elevated risk of MTC. MTC is a rare cancer regardless (about 3% of thyroid cancers). Current evidence does not show that GLP-1 medications increase MTC risk in humans at clinical doses — but the data will continue to accumulate.
If you have hypothyroidism (underactive thyroid), GLP-1 does not directly interfere with thyroid function or thyroid medication. However, weight loss can affect levothyroxine dosing needs — your thyroid levels should be checked after significant weight loss to ensure your dose is still appropriate.
Getting 100g+ of protein daily on a reduced appetite is hard. Strategic timing makes it more achievable — and more effective for muscle preservation.
Medication helps with appetite. But the mental skills for sustainable weight management — resilience, flexibility, self-compassion — must be built intentionally.
People who share their journey with a community — online or in person — consistently achieve better outcomes. Here's why, and where to find yours.